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Vaccination for hepatitis B virus (HBV) infection and treatment for chronic 
hepatitis B (CHB), while effective for primary prevention and control of the disease, still 
have their limitations.  Global coverage of HBV immunization needs improvement. 
Several patient populations are noted to have suboptimal seroprotective rates after HBV 
vaccination. There are currently several potential new vaccines undergoing animal and 
human studies, most notably vaccines containing immunostimulatory DNA sequences. 
Long-term nucleoside analogue therapy is necessary in achieving permanent virologic 
suppression. Potential new treatments explore new mechanisms of action, including the 
inhibition of hepatitis B surface antigen release, targeting anti-fibrotic mechanism, and 
immunomodulation through novel interferons and therapeutic vaccines. The clinical 
application of potential new vaccines and therapies would enhance the prevention of 





 It is estimated that 2 billion people worldwide have been exposed to the hepatitis 
B virus (HBV) (1). Four hundred million patients are infected with chronic hepatitis B 
(CHB), with an estimated 600,000 deaths annually from its associated complications 
(2). The last few decades has witnessed remarkable progress in the treatment and 
prevention of CHB. The introduction of universal HBV vaccination has markedly 
reduced the prevalence of HBV infection (3, 4). Recent years have also seen a drastic 
increase in therapeutic options in CHB. Permanent virologic suppression, and 
sometimes even hepatitis B surface antigen (HBsAg) seroclearance, can now be 
achieved (5). Nevertheless, both vaccination and treatment in CHB still have their  
limitations. Future potential improvements in vaccination and therapy will be discussed 
thoroughly in this review. 
 
Vaccination – current standards and limitations 
 The first HBV vaccines being introduced in 1982 were plasma-derived, and with 
improvements in recombinant DNA technology, were gradually replaced by 
recombinant-based vaccines (6). Serum antibody to the hepatitis B surface antigen 
(anti-HBs) of ≥ 10 mIU/mL is defined as a protective level. Currently, 162 countries have 
already implemented universal HBV vaccination programs (7), although a World Health 
Organization report in 2006 found actual implementation of vaccination among 
newborns to be only 26 to 36% (8). 
 A study in Taiwan by Ni et al followed up 18,779 vaccinated newborns for 20 
years. They found the rate of HBsAg positivity to be only 1.2% (4). Other Taiwanese 
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studies established the efficacy of universal vaccination in reducing fulminant hepatic 
failure (9, 10) and hepatocellular carcinoma (HCC) (11). Studies in Hong Kong also 
confirmed the efficacy of both plasma-derived and recombinant-based vaccines without 
booster doses up to 22 years of follow-up, with highly effective anamnestic responses in 
patients with low anti-HBs titers i.e. a significant increase in anti-HBs titers indicating 
exposure to HBV without development of HBV infection. (12-15). Studies in Italy and 
Alaska, regions with an intermediate endemicity of CHB, also found universal HBV 
vaccination to achieve a similar efficacy (16, 17). A meta-analysis of 42 separate 
cohorts found the cumulative incidence of HBV breakthrough infection in 
immunocompetent subjects to be 0.7% (18). The occurrence of vaccine-escape HBV 
mutants, initially a concern when discovered (19), was noted to be of limited prevalence, 
probably due to the replicative weakness of the mutant virus (20, 21). 
 Factors associated with failure of the HBV vaccine are listed in Table 1. Identified 
risk factors for vaccine failure among newborns include hepatitis B e antigen (HBeAg)-
positivity and a high viral load in HBsAg-positive mothers (4, 22). In addition, current 
HBV vaccines are noted to be suboptimal among adult populations with impaired 
immunity. Rates of seroprotection are lower with increasing age, obesity, smoking, 
diabetes and renal disease (23-25). In patients with end-stage renal disease (ESRD) 
receiving hemodialysis, response rates could be as low as 50 to 70% (26, 27), 
especially among patients with co-existing hepatitis C infection (28) and poor nutritional 
status (29). Outbreaks of HBV infection were still reported among hemodialysis units in 
developed countries (30). The response rates among patients with human 
immunodeficiency virus (HIV) infection are also lower (31, 32); using additional booster 
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doses and increasing the vaccine dose in such subjects only attained 1-year response 
rates of 58.8% to 63.0% (33, 34). Other patient groups prone to vaccine failure include 
chronic alcoholics with overt liver disease (35) and recipients of liver (36) and renal (37) 
transplant. 
 Hence, while universal HBV vaccination has a profound impact in the prevention 
of HBV transmission, there are two areas needing improvement: increasing global 
vaccination coverage, and enhancing response rates among the suboptimal response 
groups mentioned above. The first aspect requires international collaborative efforts by 
governments of endemic countries, the World Health Organization and different non-
profit organizations. The following sections will concentrate on the second aspect. 
 
Enhancing vaccination response 
 A recent study analyzed data from 2,356 children born to HBsAg-positive 
mothers in Taiwan found children born to HBeAg-positive mothers to have a higher 
prevalence of HBsAg-positivity compared to children born to HBeAg-negative mothers 
(9.26% and 0.23% respectively, p <0.001) (22). The authors suggested utilizing serum 
HBeAg in addition to HBsAg as screening tools to identify vaccinated children at high 
risk of developing CHB. Prospective trials would be needed to justify its cost-
effectiveness.  
Nucleoside analogue therapy in HBeAg-positive mothers has been shown to 
reduce perinatal transmission. In two recent studies, telbivudine treatment in HBeAg-
positive mothers, starting in the second or third trimester, was associated with a 
significant reduction in rates of perinatal transmission up to 28 weeks after delivery (38, 
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39). There are also studies showing the administration of hepatitis B immunoglobulin 
(HBIG) to either HBsAg-positive mothers (40) or newborns (two-dose injections) (41) is 
able to improve vaccine responsiveness. Long-term follow-up results of the above 
studies would be needed to ascertain the efficacy of both antenatal nucleoside 
analogue therapy and perinatal HBIG administration. 
Various strategies have also been employed to improve vaccine responsiveness 
in high-risk adults (Table 1). Intradermal vaccination, when given to patients with ESRD, 
is able to achieve higher rates of anti-HBs positivity (42, 43), although an improved 
response was not reproduced among patients with HIV infection (44, 45). Increasing the 
vaccine dosage among patients with ESRD can also improve vaccine response (46). 
Other suggested approaches include improving the vaccine adjuvant formula (47, 48), 
using plasmid DNA vaccines that encode HBsAg (49, 50), and administrating HBsAg-
pulsed blood dendritic cells (51). Many such suggested methods are still undergoing in 
animal studies. 
There is currently one promising vaccine that has already undergone multiple 
clinical trials – the hepatitis B surface antigen-1018 ISS adjuvant containing vaccine 
(HELIPSAV). 
 
Hepatitis B surface antigen-1018 ISS adjuvant containing vaccine (HELIPSAV) 
Immunostimulatory DNA sequences (ISS) are unmethylated cytosine 
phosphoguanosine (CpG) motifs that are found in various viruses, including HBV, but 
are rare in mammalian cells (52). These CpG motifs are recognized by toll-like receptor 
9, resulting in the preferential activation of type 1 (TH1) immune response that 
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subsequently amplifies adaptive immune responses (53). Several cytokines, including 
interleukin-12 and type I interferon (IFN) secreted by dendritic cells, are involved in this 
immune process (54). As a result, synthetic ISS are attractive vaccine adjuvants that 
stimulate specific pathways critical to immune response regulation, resulting in minimal 
toxicity (55).  
The ISS contained in HELIPSAV is a 22-mer phosphorothioate oligonucleotide, 
which is mixed with 20 µg of yeast (56). Excellent protective anti-HBs titers and good 
tolerability were noted in initials phase I studies (57). This was followed by a phase II 
comparative study using a licensed recombinant HBV vaccine among 99 healthy 
subjects aged 18 to 28 years. A greater proportion of HELIPSAV-treated recipients had 
a seroprotective anti-HBs levels at week 28 after when compared to those given 
recombinant HBV vaccine (100% and 64% respectively, p <0.001). HELIPSAV-treated 
group also had higher geometric mean titers than the recombinant vaccination group 
(2,074 versus 32 mIU/mL) (58).  
 The phase III results of HELIPSAV have been recently published (59). The first 
study, involving 2,415 healthy subjects aged 11 to 55 compared two doses of 
HELIPSAV versus three doses of recombinant HBV vaccination. HELIPSAV was able to 
achieve a higher seroprotective rates when compared to recombinant vaccine at the 
primary immunogenicity endpoint (95.1% and 81.1% respectively). Another phase III 
study investigated the efficacy of HELIPSAV in 420 healthy subjects aged 40 to 70 
years and seronegative to HBsAg, anti-HBs and antibody to the hepatitis B core antigen 
(anti-HBc) (60). The seroprotective rate of HELIPSAV was significantly higher at week 
50 when compared to recombinant vaccine (100% versus 68.6%). A third study 
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involving 2,449 participants aged 40-70 found HELIPSAV to achieve a seroprotective 
rates of 94.6%, 94.7% and 95.6% in males, obese subjects and smokers respectively. 
The seroprotective rates in the recombinant vaccine group among these three subject 
populations were only 67.8%, 65.4% and 65.3% respectively (61). In all studies, 
HELIPSAV was well-tolerated with similar safety profiles when compared to the 
recombinant vaccine.  
 The report of a case of Wegener’s granulomatosis 171 days after the second 
dose of HELIPSAV  (59) led to the vaccine being put on hold by the United States Food 
and Drug Administration in 2008 (62). However, clinical hold on HELIPSAV has been 
lifted since September 2009 after the provision of additional safety data by the 
manufacturing pharmaceutical company. 
 
Other vaccine adjuvants 
Other clinical trials in human subjects are summarized in Table 2. CPG 7909 is 
another CpG motif-based HBV vaccine adjuvant that has been found effective in phase 
I studies (63) and phase II studies involving HIV-infected subjects (64). Vaccine 
adjuvants systems that stimulate both cellular and antibody immune responses have 
been recently proven to be effective against malaria (65), and a similar system known 
as AS02, using monophosphoryl lipid A and Quillaja saponaria as vaccine adjuvants is 
also effective against HBV (66) , including in patients with renal insufficiency (67). There 
are also oral  (49) and intranasal (68) HBV vaccines undergoing clinical evaluation.  
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Information on HBV vaccines still in the phase of animal studies has been 
described in detail elsewhere (69, 70). Therapeutic vaccines aimed at CHB treatment 
would be described in a subsequent section. 
 
Treatment of chronic hepatitis B – current standards 
 Treatment of CHB has been revolutionized in the last two decades. Sustained 
and profound virologic suppression is now possible with continuous nucleoside 
analogue therapy (71, 72). These can result in a reduction in the incidence of cirrhotic 
complications and HCC (73, 74), as well as in reversing biopsy-proven cirrhosis (75). 
Certain CHB populations also respond satisfactorily to pegylated IFN therapy (76). 
Despite the favorable responses achieved with current available therapy, there 
are definitely aspects for improvement. Pegylated IFN therapy is still limited by its 
suboptimal response rate in certain CHB populations and its side-effect profile (77). 
Concerning nucleoside analogue therapy, HBsAg seroclearance, the ultimate treatment 
endpoint, is rarely seen (78). A prolonged treatment duration with potent nucleoside 
analogue therapy is needed in order to achieve histologic regression of fibrosis or 
cirrhosis (75). The reduction in the incidence of HCC, though significant, is not absolute 
(79). Lastly, no treatment can totally eradicate HBV in infected individuals. This ultimate 
objective may not be achievable since HBV forms highly stable covalently closed 
circular DNA (cccDNA) in the hepatocyte nuclei, as well as integrates into the host 
genome from the early stage of the infection. 
An exhaustive summary of novel anti-HBV drugs undergoing human and animal 
trials can be found elsewhere (80). This review concentrates on therapies with the 
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potential to be approved for widespread use in the foreseeable future. These include 
novel nucleoside analogues, HBsAg release inhibitors, novel IFNs, anti-fibrotic agents 
and therapeutic vaccines (Table 3). 
 
Novel reverse transcriptase inhibitors 
 Given the established efficacy of nucleos(t)ide analogues in controlling CHB 
infection, there are several novel drugs that inhibit the reverse transcriptase involved in 




 Besifovir is an acyclic nucleotide phosphonate with its chemical structure similar 
to that of adefovir and tenofovir (81). It is a prodrug which is converted to LB-80331 
through deacetylation in both the liver and intestine, then further oxidized to LB-80317, 
the active metabolite with antiviral effect towards HBV (Figure 1). LB-80317, unlike the 
prodrugs of adefovir and tenofovir, uses guanine instead of adenine as its base moiety, 
which contributes to an improved drug efficacy due to the lower intracellular 
concentrations of potentially competing guanine nucleotides compared to adenine 
nucleotides (82). Preclinical studies have found besifovir to show potent antiviral 
efficacy against both wild-type and drug-resistant HBV, with little reduction in 
mitochondrial DNA or lactic acid accumulation. Animal studies also found besifovir , 
when used in a similar dose as adefovir, to be 45 times less nephrotoxic (81).  
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A randomized placebo-controlled phase Ib dose escalation study of besifovir  
was performed in 29 Asian HBeAg-positive CHB patients for 4 weeks with a 12-week 
follow-up period (83).  The maximum median HBV DNA reductions were 3.05, 4.20, 
3.67 and 3.68 log copies/mL for doses 30, 60, 120 and 240 mg respectively. All 
reductions in viral loads were significantly greater when compared to placebo (p = 
0.011).  
A phase II, open-label, multicenter, dose escalation study was performed in 65 
lamivudine-resistant HBeAg-positive CHB patients (84). Besifovir was given together 
with lamivudine for 4 weeks, then followed by 8 weeks of besifovir monotherapy, 
subsequently followed by 24 weeks of adefovir. The mean HBV DNA reductions from 
baseline were 2.81, 3.21, 3.92, 4.16 and 4.00 log copies/mL for doses 30, 60, 90, 150 
and 240 mg respectively. The degree of HBV DNA suppression at week 12 was dose-
dependent (p <0.001). The drug was also well-tolerated with no drug-related adverse 
events reported. Another phase IIb multicenter study compared the efficacy and safety 
of besifovir with entecavir up to 48 weeks (85, 86). One hundred and fifteen CHB 
patients were randomized in a ratio of 1:1:1 to receive either besifovir 90 mg, besifovir 
150 mg or entecavir 0.5 mg daily. After 48 weeks, besifovir 90 mg and 150 mg were 
found to have similar rates of virologic suppression when compared with entecavir 
(67.7%, 81.8% and 80.0% respectively achieving HBV DNA <60 IU/mL, p >0.05). Rates 
of HBeAg seroconversion were also comparable (21.1%, 16.7% and 14.3% 
respectively, p >0.05). Full sequencing of the HBV polymerase region during follow-up 
did not detect any resistant mutations. Both doses of besifovir were significantly 
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associated with the lowering of L-carnitine levels, which were normalized in all patients 
with carnitine replacement. No other drug-related adverse events were reported. 
With its high potency, besifovir may find its place in the future as a third first-line 
agent, both for treatment-naïve as well as for lamivudine-resistant patients. 
 
Lagociclovir 
 Lagociclovir valactate (also known as MIV-210) is a prodrug of 3’-fluoro-2’, 3’-
dideoxyguanosine (FLG). Animal studies have found FLG to be a potent inhibitor of 
hepadnavirueses, which includes HBV (87), and is active against lamivudine-, adefovir- 
and entecavir-resistant HBV (88).  
A woodchuck model involving different doses of lagociclovir found serum HBV 
DNA to decrease by more than 7 log after 10 weeks of therapy. There was also a 2 log 
decrease in intrahepatic covalently closed circular DNA (cccDNA). The reduction in 
HBV DNA, when compared to previous woodchuck models, was comparable to 
entecavir and better than lamivudine or adefovir (89). Phase I and II clinical studies are 
currently ongoing in Europe and Asia (80). 
 
HBsAg release inhibitors  
 All currently available oral anti-HBV medication are nucleos(t)ide analogues, 
which target the activity of reverse transcriptase in viral replication. There has been 
research aimed at developing novel drugs targeting other areas in the biology of HBV. 
The inhibition of HBsAg release is one such potential target, especially since the 
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therapeutic reduction of serum HBsAg is associated with a corresponding decline in 
intrahepatic cccDNA (90).  
 The HepG2 and HepA2 cell lines transfected by HBV have been applied as in 
vitro models in evaluating the efficacy of novel anti-HBV drugs. A study reported 
artesunate-containing herbal extracts were able to effectively inhibit serum HBsAg 
release in HepG2 cells (91). Serum HBsAg production was also similarly suppressed by 
pyranocoumarin analogues in HepA2 cells based on extracts isolated from the 
medicinal plant Clausena excavate (92). An aromatically substituted tetrahydro-
tetrazolo-(1, 5-a)-pyrimidine known as HBF-0259 was able to suppress HBsAg 
production in HepG2 cells without affecting HBeAg or HBV DNA synthesis (93). A 
chemically improved version of HBF-0259 was able to achieve potent HBsAg inhibition 
in HBV-transgenic mice and was effective against both wild-type and drug-resistant 
HBV. No signs of toxicity through serum chemistry analysis were noted (94). 
 
REP 9AC 
 REP 9AC is a nucleic acid-based amphipathic polymer, which belongs to a new 
class of antiviral compounds based on the sequence-independent activity of 
phosphorothioated oligonucleotides. Similar amphipathic molecules have been found to 
exhibit potent antiviral activity against human immunodeficiency virus (HIV) (95), 
hepatitis C virus (96) and cytomegalovirus (97). REP 9AC facilities innate immunity 
against HBV by inhibiting release of subviral particles, including HBsAg, from infected 
hepatocytes. Both HBsAg and HBeAg have been reported to abrogate the toll-like 
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receptor induced innate response against HBV, resulting in the persistence of HBV 
infection (98). 
 Phase I/II studies of REP 9AC are currently ongoing. Interim reports found the 
intravenous infusion of REP 9AC resulted in >99.5% reduction in HBsAg in 7 of 8 
patients within 7 days to 32 weeks of treatment, with a corresponding reduction in 
serum HBV DNA also noted. After stopping therapy, 3 patients maintained serum HBV 
DNA <500 copies/mL and HBsAg <10 IU/mL, while the other patients had >90% 
reduction in HBsAg and 2 to 7 log reductions in HBV DNA (99, 100). These preliminary 
results indicate HBsAg release inhibitor could become an important new tool in the 
control of CHB in the future. 
 
Interferon-lambda (IFN-λ) 
 IFN-based therapy in CHB, while offering the advantage of a finite duration of 
therapy and the slightly higher rate of HBsAg seroclearance, is associated with high 
rates of virologic rebound after treatment cessation and an unfavorable side-effect 
profile (101). The multiple side-effects seen are related to the abundant IFN-α receptor 
distributed throughout the whole human body. IFN-λ (Figure 2), discovered in 2003 
(102), induces antiviral response via a pathway similar to IFN-α and -β. IFN-λ receptors, 
although expressed in high amounts in hepatocytes(103), are not found in other human 
cells including fibroblasts, monocytes, adipocytes or primary central nervous system 




 IFN-λ, despite its molecular difference, shares similar biological characteristics 
with IFN-α and –β. The stimulation of IFN-λ, similar to IFN-α and –β, involves toll-like 
receptors (102, 106). All three IFNs activate IFN-stimulated regulatory factor 3 and 
induces the expression of genes containing IFN-stimulated response elements (106). 
Nevertheless, IFN-λ does not bind to the IFN-α receptor complex, but triggers its cellular 
activity through a receptor consisting of two subunits: an interleukin-10 receptor and an 
IFN-λ receptor 1 (107). 
IFN-α inhibits HBV replication by preventing the assembly of viral RNA-
containing capsids in the cytoplasm (108). IFN-λ operates through a similar molecular 
mechanism as demonstrated by a study using murine hepatocytes (107). Subsequent 
studies using human hepatocytes also demonstrated a similar efficacy in inhibiting HBV 
replication (109, 110). 
Phase I and II studies in CHB patients are currently ongoing. From published 
data on pegylated IFN-λ in chonic hepatitis C patients, IFN-λ was well-tolerated with 
minimal adverse effects (111). The efficacy of IFN-λ was reduced in chronic hepatitis C 
patients with prior IFN-α treatment (105)  Its effect against HBV will have to await the 
results of current clinical trials. 
  
 
FG-3019 – novel antifibrotic agent 
Hepatic fibrogenesis is a common pathway of liver damage seen in many chronic 
liver diseases, including CHB. The development of anti-fibrotic agents aimed at 
regressing liver fibrosis has thus aroused great interest. Fibrogenic mechanisms are 
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dependent on the interplay of many pro- and anti-fibrotic cytokines, of which 
transforming growth factor beta (TGF-β) has been viewed as the ―master‖ cytokine 
crucial for the advancement of fibrosis (112). Important regulators of these cytokines are 
the connective tissue growth factors (CTGFs). Initially discovered in 1991 in the 
conditioned medium of human umbilical vein endothelial cells (113),  CTGF consists of 
four domains (Figure 3), and up-regulates the majority of pro-fibrotic cytokines, including 
TGF-β, hence promoting hepatic fibrosis (114). CTGF expression has been noted in 
hepatic stellate cells (HSCs), the main producers of extracellular matrix proteins related 
to fibrosis, in both experimental models and human patients (115, 116). Hepatocytes 
infected by HBV are also noted to have increased CTGF and TGF-β up-regulation 
(117). Fibrogenesis is likely triggered by the X protein of HBV, with human and rat 
HSCs exposed to the X protein showing an increased expression of CTGF, TGF-beta 
and other fibrogenic cytokines (118). 
FG-3019 is an anti-CTGF monoclonal antibody that is designed to inhibit to 
inhibit TGF-β related fibrosis. The second domain of CTGF, which is homologous to the 
von Willebrand factor type C repeat, is the binding site of FG-301 (Figure 3). FG-3019 
has the potential to be used in multiple disease entities in which fibrogenesis is a major 
pathophysiological element, including pulmonary fibrosis, pancreatic cancer, kidney 
disease and liver fibrosis. Animal studies have found FG-3019 able to improve 
histologic signs of liver fibrosis by reducing the accumulation of extracellular matrix in 
the liver and reduce the number of activated HSCs  (119). Hydroxyproline:proline 
(Hyp:Pro) ratios, which quantitatively scores organ fibrosis by measuring the collagen 
content relative to total organ protein, are increased by the co-administration of CTGF 
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and TG-Fβ. Hyp:Pro ratios are however significantly reduced in the liver through the 
administration of FG-3019 (120).  
Phase I and II studies are currently ongoing in South East Asia, investigating the 
effect of FG-3019 or placebo with entecavir in CHB. FG-3019 is well-tolerated with no 
drug-related adverse effects, as shown in clinical trials involving pancreatic cancer and 
diabetic kidney disease (121, 122). 
   
Therapeutic vaccines 
 A key element in the chronicity of HBV infection is the weakened innate immunity 
system resulting in the failure of viral clearance. Hepatocytes infected by HBV inhibit 
CD8 T cells, leading to the impairment of T-cell function and reduction of anti-viral 
cytokines (e.g. IFN-γ and tumor necrosis factor-α) (123). Therapeutic vaccination is thus 
a potential strategy which could theoretically eradicate HBV by strengthening the 
patient’s immune response (124), although the results of such trials have not been 
satisfactory.  
 A double-blind placebo controlled phase II trial used a therapeutic vaccine 
containing HBsAg–anti-HBs immune complexes in HBeAg-positive CHB. Although 
increased rates of HBeAg seroconversion were seen in the therapeutic vaccine arm, 
there was no difference in the rates of virologic suppression (125). Moderate levels of 
serum HBV DNA and HBsAg levels were still seen 24 weeks post-treatment (126). DNA 
vaccines are gaining in popularity given their ability to induce both humoral and cellular 
immune responses. Two phase I studies investigated therapeutic plasmid DNA 
vaccines based on recombinant HBsAg proteins, which, although well-tolerated and 
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immunologically effective, did not result in significant HBV DNA suppression (127, 128). 
Another study found combining a DNA vaccine containing recombinant interleukin-12 
with lamivudine did not improve rates of virologic suppression (129). DNA vaccines also 
fail to maintain virologic remission after cessation of nucleoside analogue therapy (130).  
 One promising therapeutic vaccine currently undergoing clinical trials is DV-601. 
This vaccine comprises of recombinant HBsAg and hepatitis B core antigen (HBcAg), 
and is engineered to stimulate a broad spectrum of T cells. In a phase I dose-escalation 
study, 14 CHB patients were started on concurrent entecavir and DV-601. A preliminary 
analysis showed all patients to have substantial reductions in both serum HBV DNA and 
HBsAg titers; HBeAg titers were also reduced in HBeAg-positive patients. Anti-HBs and 
antibody to the hepatitis B e antigen (anti-HBe) developed in higher dose groups. The 
vaccine was also well-tolerated (131). 
 The problem with therapeutic vaccines is that most CHB patients, especially 
those from Asia, Africa and certain Mediterranean countries, have been exposed to the 
virus since early childhood when the immune system is not yet fully matured. These 
carriers have also been exposed to large amounts of HBsAg for long periods of time. 
With the virus forming cccDNA inside the hepatocyte nuclei as well as viral integration 
into the host genome, CHB patients might not mount a satisfactory immune response to 
therapeutic vaccination.  
 
Future directions 
 CHB is now both preventable and treatable due to the remarkable advances 
achieved in the last three decades. Yet, eliminating and eradicating HBV totally remains 
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difficult. In the era of universal immunization, HBV vaccination can be further improved 
in three areas: increasing global coverage, recognizing HBsAg-positive mothers with 
increased risk of mother-to-infant transmission, and improving responsiveness among 
high-risk individuals. The use of nucleoside analogues in high-risk HBsAg-positive 
mothers, while effective, requires long-term data of affected infants for validation, 
especially if universal implementation is planned. HELIPSAV can achieve high 
seroprotective rates in hyporesponsive individuals, and its future global availability 
would be crucial in the prevention of HBV among high-risk subjects. 
 Concerning CHB treatment, long-term nucleoside analogue therapy is needed to 
maintain permanent virologic suppression. Potential new therapies explore new 
methods of HBV control, including inhibiting HBsAg release, improving 
immunomodulation and targeting mechanisms of fibrosis. Different mechanisms of 
action could signify the potential for combination therapies in the future. Yet it is still 
uncertain if these methods could achieve HBsAg seroclearance, or more importantly, 
reduce and eradicate HBV cccDNA from infected hepatocytes. To elevate the aim of 
HBV therapeutics from virologic suppression to eradication, future studies on 
intrahepatic virologic kinetics are needed, with the focus on investigating mechanisms of 
intrahepatic cccDNA decline in patients achieving spontaneous or treatment-related 
HBsAg seroclearance. Until then, long-term nucleoside analogue therapy would remain 
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Figure 1. The molecular structure of besifovir (LB-80380), and its two metabolites LB-
80331 and LB-80317. 
Figure 2. The molecular structure of interferon-lambda. 
Figure 3. The 4 domains of connective tissue growth factor (CTGF), with the second 
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Table 1. Factors associated with HBV vaccination failure 
Subjects Factors Methods to improve vaccine 
response 
Newborn HBsAg-positive mothers (especially 
HBeAg-positive) 
 HBsAg / HBeAg 
screening 
 Nucleoside analogue 
therapy for high-risk 
mothers 
 HBIG for high-risk 
mothers / infants 
 Mothers with high viral load 
Adult Increasing age  ISS-based vaccination 
(e.g. HELIPSAV) 
 Intradermal vaccination 
 Increasing vaccination 
dose 
 Improving vaccine 
adjuvant formula 
 Using plasmid DNA 
vaccines 





 End-stage renal disease 
 HIV infection 
 Alcoholics with overt liver disease 
 Recipients of liver / kidney 
transplantation 
HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e 
antigen; HBIG, hepatitis B immunoglobulin; ISS, immunostimulatory DNA sequences; 
HIV, human immunodeficiency virus. 
Table
Table 2. Promising HBV vaccine adjuvants undergoing clinical trials in human subjects 





Phase III Effective in normal and 
hyporesponsive subjects 
CPG 7909 Immunostimulatory 
CpG 
Phase II Effective in HIV-infected 
individuals 
AS02 Monophosphoryl lipid 
A and QS 21 




DNA vaccine taken 
orally 
Phase I Humoral and cell-mediated 
responses induced in 
hyporesponsive subjects 
NASVAC Recombinant HBsAg 
and HBcAg taken 
intranasally 
Phase I Seroprotective up to 90 days 
CpG, cytosine phosphoguanosine; QS, Quillaja saponaria; HBsAg, hepatitis B surface 
antigen; HBcAg, hepatitis B core antigen 
Table 3. Promising therapeutic options for chronic hepatitis B 
 





Phase II High rates of virologic 





Phase I Significant reduction in 
cccDNA in woodchuck model 
REP 9AC HBsAg release 
inhibitor 
Phase II Significant serum HBsAg 
reduction 
Interferon-λ Interferon Phase II Inhibit HBV replication in 
animal studies 
FG-3019 Connective tissue 
growth factor 




Phase I Significant reductions in 
serum HBV DNA, HBsAg and 
HBeAg 
 
